Richard E Kanner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/916737/publications.pdf

Version: 2024-02-01

46 papers

2,569 citations

304368

22

h-index

233125 45 g-index

49 all docs 49 docs citations

49 times ranked 3388 citing authors

#	Article	IF	CITATIONS
1	Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. New England Journal of Medicine, 2016, 374, 1811-1821.	13.9	526
2	Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): TableÂ1. Thorax, 2014, 69, 492-495.	2.7	277
3	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine, the, 2017, 5, 619-626.	5.2	219
4	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine, the, 2017, 5, 956-967.	5.2	211
5	SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 794-806.	2.5	180
6	Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax, 2014, 69, 987-996.	2.7	114
7	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 473-481.	2.5	101
8	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genetics, 2016, 12, e1006011.	1.5	88
9	Human airway branch variation and chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E974-E981.	3.3	80
10	Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine, the, 2021, 9, 1241-1254.	5.2	80
11	Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 464-472.	2.5	59
12	Association of Long-term Ambient Ozone Exposure With Respiratory Morbidity in Smokers. JAMA Internal Medicine, 2020, 180, 106.	2.6	49
13	Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 987-997.	2.5	38
14	Selection of Spirometric Measurements in a Clinical Trial, the Lung Health Study. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 675-681.	2.5	33
15	Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort. Annals of the American Thoracic Society, 2018, 15, 808-816.	1.5	32
16	Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS. Annals of the American Thoracic Society, 2018, 15, 710-717.	1.5	32
17	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Annals of the American Thoracic Society, 2017, 14, 636-642.	1.5	30
18	Differentiation of quantitative CT imaging phenotypes in asthma versus COPD. BMJ Open Respiratory Research, 2017, 4, e000252.	1.2	30

#	Article	IF	Citations
19	Effect of Naturally Occurring Ozone Air Pollution Episodes on Pulmonary Oxidative Stress and Inflammation. International Journal of Environmental Research and Public Health, 2015, 12, 5061-5075.	1.2	28
20	Genome-wide association study of lung function and clinical implication in heavy smokers. BMC Medical Genetics, 2018, 19, 134.	2.1	28
21	Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort. Annals of the American Thoracic Society, 2018, 15, 1411-1419.	1.5	27
22	Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). Respiratory Research, 2019, 20, 153.	1.4	25
23	Serum IgG Levels and Risk of COPD Hospitalization. Chest, 2020, 158, 1420-1430.	0.4	22
24	Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Respiratory Research, 2018, 19, 178.	1.4	20
25	Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. Scientific Reports, 2019, 9, 11367.	1.6	20
26	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. PLoS ONE, 2017, 12, e0184606.	1.1	20
27	Clinical Phenotypes of Atopy and Asthma in COPD. Chest, 2020, 158, 2333-2345.	0.4	19
28	NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort. Respiratory Medicine, 2018, 140, 87-93.	1.3	18
29	Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 536-545.	2.5	17
30	<p>Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis</p> . International Journal of COPD, 2019, Volume 14, 2927-2938.	0.9	16
31	Characteristics of Alpha-1 Antitrypsin–Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2015, 12, 1796-1804.	1.5	15
32	Structural and Functional Features on Quantitative Chest Computed Tomography in the Korean Asian versus the White American Healthy Non-Smokers. Korean Journal of Radiology, 2019, 20, 1236.	1.5	13
33	Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. Respiratory Research, 2018, 19, 223.	1.4	12
34	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. Scientific Reports, 2021, 11, 4916.	1.6	12
35	<p>Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort</p> . International Journal of COPD, 2020, Volume 15, 2467-2476.	0.9	11
36	A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 346-361.	0.5	9

#	Article	IF	CITATIONS
37	Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR. Science of the Total Environment, 2022, 829, 154694.	3.9	9
38	The influence of social support on COPD outcomes mediated by depression. PLoS ONE, 2021, 16, e0245478.	1.1	8
39	Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). International Journal of COPD, 2021, Volume 16, 1477-1496.	0.9	8
40	Ratio of FEV1/Slow Vital Capacity ofÂ< 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function. Chest, 2021, 160, 94-103.	0.4	8
41	Comparative Impact of Depressive Symptoms and FEV ₁ % on Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2022, 19, 171-178.	1.5	7
42	Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2022, 9, 111-121.	0.5	6
43	Defining Resilience to Smoking Related Lung Disease: A Modified Delphi Approach from SPIROMICS. Annals of the American Thoracic Society, 2021, 18, 1822-1831.	1.5	5
44	Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 370-381.	0.5	5
45	<p>Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the Spiromics Cohort</p> . International Journal of COPD, 2020, Volume 15, 1887-1898.	0.9	2
46	Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 326-335.	0.5	0